LONG-TERM EFFECT OF CONTINUOUS POSITIVE AIRWAY PRESSURE THERAPY (CPAP) IN HYPERTENSIVE PATIENTS WITH SLEEP APNEA AND METABOLIC IMPAIRMENT

Objective: Obstructive sleep apnea (OSA) is associated with the high prevalence of cardiovascular diseases, and such disease manifestations as obesity, arterial hypertension (AH), violation of carbohydrate metabolism, dyslipidemia and endothelial dysfunction. However, the effects of Continuous Positive Airway Pressure therapy (Continuous Positive Airway Pressure — CPAP therapy) on the normalization of blood pressure in patients with OAS+AH are poorly understood and poorly studied. The aim of the study was to investigate 12-month effects of long-term CPAP-therapy with auto-adaptation to inhalation and exhalation (A-Flex therapy) on blood pressure in patients with OSA+AH. Methods: To the prospective single-center study were included 177 patients with snoring, metabolic disorders, obstructive sleep apnea, and hypertension with the established drug therapy (138 men [78%] and 37 females [21%]), in age interval of 35-75 years (56,4 ± 9,4) which apnea-hypopnea index (AHI) > 5 event/hour. The night polygraphy study (PG) was performed to calculate AHI, oxygen desaturation index (ODI), mean nocturnal saturation (Sp02 mean) by the rules of American Academy of Sleep Medicine (AASM). Optimal level of A-Flex therapy was adjusted at home. AHI, the level of air leakage, average pressure and compliance to CPAP treatment were established in accordance with international requirements. Results: After 12 months of A-Flex therapy we found a significant decrease of level of systolic and diastolic blood pressure. The group of CPAP-therapy has decreased daytime SBP on -5.9 mmHg (95% Cl from -3.2 to -7.1; P=0.02) and night SBP on -4.1 mmHg (95% Cl from -6.1 to -2.6; P=0.01). Similar dynamics was observed in variations of DBP. The group of CPAP-therapy decreased daytime DBP on -1.1 mm Hg (95% Cl from -2.2 to -0.5; P=0.02) and nighttime DBP on -5.1 mm Hg (95% Cl from -7.2 to -3.5; P=0.01). In addition, the group of CPAP-therapy have clinical changing of excessive daytime sleepiness, expanding physical activity, normalization of night sleep. Conclusions: The 12-month A-Flex therapy in OSA patients with AH has a significant therapeutic effect of stabilization systolic and diastolic blood pressure. The long-term 12-month A-Flex therapy has to reduce the risks of cardiovascular events in moderate and severe OSA patients with acute metabolic manifestations and arterial hypertension.

1. Lombardi C1., Tobaldini E., Montano N., Losurdo A., Parati G. Obstructive Sleep Apnea Syndrome (OSAS) and Cardiovascular System. .Med. Lav. 2017 Aug 28; 108(4): 276-282. doi: 10.23749/mdl.v108i4.6427. PMID: 28853425.

2. Floras J.S. Hypertension and Sleep Apnea. Can. J. Cardiol. 2015 Jul; 31(7): 889-97. doi: 10.1016/j.cjca.2015.05.003. PMID: 26112299.

3. Kartali N., Daskalopoulou E., Geleris P., Chatzipantazi S., Tziomalos K., Vlachogiannis E., Karagiannis A. The effect of continuous positive airway pressure therapy on blood pressure and arterial stiffness in hypertensive patients with obstructive sleep apnea. Sleep Breath. 2014 Sep; 18(3): 635-40. doi: 10.1007/s11325- 013-0926-0. PMID: 24362941.

4. Grundy S.M., Brewer H.B. Jr., Cleeman J.I., Smith S.C. Jr., Lenfant C.; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004 Jan. 27; 109(3): 433-8. doi: 10.1161/01. CIR.0000111245.75752.C6, PMID: 14744958.

5. Kushida C.A., Littner M.R., Morgenthaler T. et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005; 28: 499–521. PMID: 16171294.

6. Littner M., Hirshkowitz M., Davila D., Anderson W.M., Kushida C.A., Woodson B.T., Johnson S.F., Merrill S.W. Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the use of auto-titrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome. An American Academy of Sleep Medicine report. Sleep. 2002 Mar 15; 25(2): 143-7. PMID: 11902424.

7. Masa J.F., Jiménez A., Durán J., Capote F., Monasterio C., Mayos M., et al. Alternative methods of titrating continuous positive airway pressure: a large multicenter study. Am. J. Respir. Crit. Care Med. 2004: 170: 1218–24. PMID: 15282204

8. Mancia G., Fagard R., Narkiewicz K., Redón J., Zanchetti A., Böhm M., et al. The 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013: 31: 1281–357. doi: 10.1097/01. hjh.0000431740.32696.cc, PMID: 23817082.

9. Campos-Rodriguez F., Grilo-Reina A., Perez-Ronchel J., MerinoSanchez M., Gonzalez-Benitez M.A., Beltran-Robles M., AlmeidaGonzalez C. Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial. Chest 2006; 129(6):1459-67. doi:

10. 1378 /chest.129.6.1459, PMID: 16778262. 10. Muxfeldt E.S., Margallo V., Costa L.M., Guimarães G., Cavalcante A.H., Azevedo J.C., de Souza F., Cardoso C.R., Salles G.F. Effects of continuous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a randomized controlled trial. Hypertension 2015 Apr; 65(4): 736-42. doi: 10.1161/ HYPERTENSIONAHA.114.04852, PMID: 25601933.

11. Dorkova Z., Petrasova D., Molcanyiova A., Popovnakova M., Tkacova R. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest. 2008 Oct; 134(4): 686-92. doi: 10.1378/chest.08-0556, PMID: 18625666.